On December 7, 2022 Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, reported that it will present updated efficacy, immunogenicity and safety data from its Phase 2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (ROSALIE trial) in two poster presentations at the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress which is taking place in Geneva, Switzerland, December 7-9 2022 (Press release, Enterome, DEC 7, 2022, View Source [SID1234624857]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
EO2401 is a first-in-class OncoMimics peptide-based immunotherapy able to rapidly activate and significantly expand existing effector memory CD8+ T cells against tumor-associated driver antigens due to their strong cross-reactivity with OncoMimics peptides.
Professor Wolfgang Wick, Universitätsklinikum and German Cancer Research Center, Heidelberg (Germany) will present the two posters on Thursday December 8th at the Poster Display Session ID 44 from 12:30 to 13:15 CET.
The poster details are as follows:
Poster Details – Abstract #170P
Title: EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study
Authors: W. Wick et al.
Link to abstract can be accessed here.
Poster Details – Abstract #185P
Title: Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab
Authors: W. Wick et al.
Link to abstract can be accessed here.
In addition, Enterome will present another poster on in vitro assays and in vivo evaluations in healthy donors demonstrating that OncoMimics peptides can elicit strong immune responses against tumors through cross-reaction of pre-existing, highly prevalent (>80% in the population) CD8+ T cells against targeted Tumor-Associated Antigens (TAAs).
Poster Details – Abstract #180P
Title: Recalling pre-existing microbiota-specific T cells to target tumors
Authors: J.-M. Carpier et al.
Link to abstract can be accessed here.
About EO2401
EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics peptide-based immunotherapy. It combines three microbial-derived OncoMimics peptides that closely mimic specific cytotoxic T cell (CD8+ T cell) epitopes on the Tumor-Associated Antigens IL13Ra2, BIRC5 and FOXM1, combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2). EO2041 is designed to trigger the immune system into recognizing these epitopes on glioblastoma cells as foreign (non-self) and eliciting a targeted memory T-cell driven cell-killing response against the tumor cells.
About ROSALIE
ROSALIE (EOGBM1-18, NCT04116658) is a multicenter, open-label, Phase 1/2 trial investigating EO2401 in combination with nivolumab, and in combination with nivolumab/bevacizumab in patients with glioblastoma at first progression/recurrence after surgery and adjuvant radiotherapy/temozolomide. The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in more than 80 patients at centers in the US and Europe.